Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Key information relating to the conditional rights offering to be carried out by Bionor Pharma ASA

Bionor Pharma ASA
Posted on: 19 Aug 16




Key information relating to the conditional rights offering to be carried out by Bionor Pharma ASA

(Oslo, Norway, 19 August 2016) Reference is made to the Company's announcement regarding completion of a private placement and a contemplated rights offering published yesterday. The private placement and rights offering are conditional upon approval by the shareholders in an extraordinary general meeting (the "EGM") to be held on 9 September 2016, see separate announcement published today, 19 August 2016.

The Board has proposed to conduct a rights offering to existing shareholders as per the end of 9 September 2016 (the date of the EGM) who shall have preferential rights to subscribe for new shares in the rights offering, provided such shareholders are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action. Subscription rights will not be awarded based on the shares subscribed for in the private placement. The subscription period in the rights offering will be two weeks and will commence as soon as practically possible after the EGM and the approval of a prospectus.

Key information in relation to the conditional rights offering:

Date on which the terms and conditions of the
rights offering were announced                                       18 August 2016

Last day including right                                               9 September 2016

Ex-date                                                                     12 September 2016

Record date                                                              13 September 2016

Date of approval                                                         9 September 2016

Maximum number of new shares in rights offering              525,000,000

Subscription price                                                                    NOK 0.10

Shall the rights be listed yes/no                                                         Yes

This information is published in accordance with the requirements of the Continuing Obligations.

Further information
Per S. Thoresen, Chairman of the Board of Directors, +47 906 14 620
Unni Hjelmaas, Acting CEO, +47 915 19 651,

About Bionor
Bionor Pharma's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to the HIV immunotherapy Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company's shareholders. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at .

Important Information
The release is not for publication or distribution, in whole or in part directly or indirectly, in or  into  Australia,  Canada,  Japan  or  the United States (including  its territories and possessions, any  state of the United States and the  District  of  Columbia).

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States.  Copies of this announcement are not being made and may not be distributed or sent into Australia Canada, Japan or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions  in certain jurisdictions. Neither the Company nor the Manager assumes any responsibility in the event there is a violation by any person of such restrictions.

The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Bionor_key information_19Aug2016

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bionor Pharma ASA via GlobeNewswire

Last updated on: 22/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.